Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dapirolizumab pegol in moderate to severe active systemic lupus erythematosus
CTR20222715Phase 3Active
- Sponsor
- ---/ 优时比贸易（上海）有限公司
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by ---/ 优时比贸易（上海）有限公司. Started Feb 2025; status: active.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20222715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222715.